Financials

  • Market Capitalization 11.9652 B
  • Employee 1 077
  • Founded 1994
  • CEO Michael M. Morrissey
  • Website www.exelixis.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ4WF8
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
15.68
Price to sales ratio
5.29
Dividends per share
Dividend yield %

Exelixis Inc

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

ニュース